קולומבי - Columvi
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01FX Other monoclonal antibodies and antibody drug conjugates | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | ||||||||||||||||||
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Columvi is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B cell lymphoma after two or more lines of systemic therapy. | ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
Â
 | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ק×××××× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | HOFFMANN LA ROCHE, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | ROCHE PHARMACEUTICALS (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 5/2023. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 24/08/2024 |
השינוי האחרון נעשה בֹ־24 באוגוסט 2024 ב־06:24